Back to BALYASNY ASSET MANAGEMENT L.P. BALYASNY ASSET MANAGEMENT L.P.

MLTXMLTX
Showing 8 of 16 quarters

Position history for BALYASNY ASSET MANAGEMENT L.P.BALYASNY ASSET MANAGEMENT L.P.'s holdings in MoonLake Immunotherapeutics Class A

BALYASNY ASSET MANAGEMENT L.P. holds 912,715 shares of MLTX (MoonLake Immunotherapeutics Class A), worth $17.8M as of 2026-Q2. The position was decreased (-14.3% shares). MLTX represents 0.0% of BALYASNY ASSET MANAGEMENT L.P.'s portfolio.

Current Value

$17.8M

Current Shares

912,715

Total Value Change

-$390,723

Total Shares Change

+552,515

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
912,715
-14.3%
$17.8M0.0%$19.47
0
2026-Q1
Decreased
1.1M
-32.2%
$19.9M0.0%$17.69
0
2025-Q4
Decreased
1.6M
-7.5%
$20.7M0.0%$13.21
0
2025-Q3
Increased
1.7M
+301.6%
$12.2M0.0%$6.24
45
2025-Q2
Increased
423,170
+436.8%
$20M0.0%$47.52
46
2025-Q1
Decreased
78,835
-61.8%
$3.1M0.0%$39.86
0
2024-Q4
Decreased
206,568
-42.6%
$11.2M0.0%$53.02
0
2024-Q3
Decreased
360,200
-38.4%
$18.2M0.0%$49.40
0

Other major holders of MLTX: FMR LLC, Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used